Search results

Filters
Close
ADDED DATE
Added date
TOPICS Please select
WATCH / LISTEN / READ TIME
ECG in Severe COVID-19 Infection
Author(s): Kapil Rajendran , Baiju Rajan , Sivaprasad Kunjukrishnapilla , et al Added: 1 year ago

Imaging & Diagnostics

Heart Failure
Research Area(s) / Expertise: Job title: Medical Director
ESC 23: The DANPACE II Trial
Author(s): Mads Brix Kronborg Added: 2 years ago
ESC 2023 — Dr Mads Brix Kronborg (Aarhus University Hospital, DE) joins us to discuss the findings from the DANPACE II Trial (NCT00236158). DANPACE II (The DANPACE Investigator Group) trial aimed to compare patients who were randomised in a 1:1 ratio to either a base rate of 60 beats per minute and rate-adaptive DDD (DDDR-60 Group) or a base rate of 40bpm and non-rate adaptive DDD (DDD-40… View more

Electrophysiology & Arrhythmia
Stavros Konstantinides
Job title: Professor for Clinical Trials and Medical Director of the Center for Thrombosis and Hemostasis
Prof Stavros Konstantinides, MD, FESC, is Professor for Clinical Trials and Medical Director of the Center for Thrombosis and Hemostasis (CTH) at the University of Mainz, Germany. He is also Professor of Cardiology at the Democritus University of Thrace, Greece. He graduated from the Aristotle University of Thessalonica, Greece, and earned his doctorate degree at the University of Freiburg,… View more
ESC 24: The SCOFF Trial
Author(s): David Ferreira Added: 1 year ago
ESC Congress 24 — Fasting prior to cardiac catheterisation surgery significantly improves patient satisfaction score.We are joined onsite by Dr David Ferreira (John Hunter Hospital, AU) to discuss the findings from the SCOFF Trial (ACTRN12622001455752), which randomized 716 patients in a 1:1 fashion to either a no fasting group, or a fasting group. The fasting group were allowed solid foods 6… View more

Intervention
HFSA 25: Excercise Effects of Aficamten Vs Metoprolol in MAPLE-HCM
Author(s): Gregory Lewis Added: 2 months ago
HFSA 25 - Aficamten improves excercise capacity compared to metoprolol in patients with obstructive hypertrophic cardiomyopathy in a prespecified analysis of the MAPLE-HCM study.Dr Gregory Lewis joins us to discuss findings from a prespecified cardiopulmonary exercise testing analysis of the MAPLE-HCM trial, which reveals divergent effects between aficamten and metoprolol on exercise performance… View more

Heart Failure
Gherardo Finocchiaro
Dr Gherardo Finocchiaro completed his undergraduate training and qualified from Trieste University (Italy) in 2007. He completed his fellowship in Cardiology in Trieste in April 2012, with particular interest in cardiomyopathies. He is now undertaking research at St George’s University Hospital, London in the field of sudden cardiac death, cardiomyopathies and athletic cardiac adaptation. View more
AHA 23 Late-Breaker Discussion: Hypertension Treatment in Nigeria Program
Author(s): Harriette Van Spall , Dike Bevis Ojji Added: 2 years ago
AHA 2023 — Investigator Dr Dike Bevis Ojji (University of Abuja, NG) talks with Late-breaker host, Dr Harriette Van Spall (McMaster University, CA) about the Hypertension Treatment in Nigeria Program (NCT04158154).The aim of this study (Washington University School of Medicine) and employing an interrupted time series design, is to assess the implementation and evaluation of a culturally- and… View more

Prevention & Chronic Conditions
Brian Halliday
Research Area(s) / Expertise: Job title: Academic Clinical Lecturer
Dr Halliday is a Senior Clinical Lecturer and BHF Intermediate Fellow at the National Heart and Lung Institute, Imperial College and Honorary Consultant Cardiologist at Royal Brompton Hospital, Guys’ and St Thomas’ NHS Trust. His research and clinical interests focus on the management of patients with cardiomyopathy and the use of cardiovascular magnetic resonance to improve treatment… View more
Klaus Witte
Research Area(s) / Expertise:
Klaus Witte is a Cardiologist at the Leeds Institute of Cardiovascular & Metabolic Medicine, Leeds, UK, where his research group focuses on patient-orientated questions with a commitment to enhancing efficacy through the personalised application of new and existing therapies in chronic heart failure (CHF).Challenging conventional teaching around heart rate and exercise capacity in CHF, Dr Witte’s… View more